Improvement of sympathetic skin responses under enzyme replacement therapy in Fabry disease

Journal of Inherited Metabolic Disease

Volumn 29, Issue 5, 2006, Pages 653-659

  Jardim, Laura B ^a,b   Gomes, I ^a   Netto, C B O ^a   Nora, D B ^a   Matte, U S ^a   Pereira, F ^a,b   Burin, M G ^a   Kalakun, L ^a   Giugliani, R ^a,b   Becker, J ^a  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AGALSIDASE ALFA;

ACTION POTENTIAL; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; ENZYME REPLACEMENT; FABRY DISEASE; HUMAN; MALE; NEUROLOGIC EXAMINATION; OPEN STUDY; PARESTHESIA; PREDICTION; SENSORY ANALYSIS; STATISTICAL SIGNIFICANCE; STIMULUS RESPONSE; STUDENT T TEST; SWEATING; SYMPATHETIC TONE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGE FACTORS; ALPHA-GALACTOSIDASE; CASE-CONTROL STUDIES; CHILD, PRESCHOOL; DNA MUTATIONAL ANALYSIS; ENZYMES; FABRY DISEASE; HUMANS; ISOENZYMES; MALE; MOLECULAR SEQUENCE DATA; MUTATION; NEUROLOGIC EXAMINATION; SKIN; TIME FACTORS;

EID: 33748713855     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-006-0339-3     Document Type: Article

References (27)

1. Baser S (1991) Sudomotor function in autonomic failure. Neurology 41: 1564-1566.
2. Beck M, Ricci R, Widmer U, et al (2004) Fabry disease: Overall effects of agalsidase alfa treatment. Eur J Clin Invest 34: 838-844.
3. Brady RO, Schiffmann R (2000) Clinical features of and recent advances in therapy for Fabry disease. JAMA 284: 2771-2775.
4. Cable WJL, Kolodny EH, Adams RD (1982) Fabry's disease: Impaired autonomic function. Neurology 32: 498-502.
5. Desnick RJ, Ioannou YA, Eng CM (2001) alpha-Galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet al Sly WS, Valle D, eds; Childs B, Kinzler KW, Vogelstein B, assoc. eds. The Metabolic and Molecular Bases of Inherited Disease, 8th edn. New York: McGraw-Hill, 3733-3774.
6. Dütsch M, Marthol H, Stemper B, Brys M, Haendl T, Hilz MJ (2002) Small fibre dysfunction predominates in Fabry neuropathy. J Clin Neurophysiol 19: 575-586.
7. Eng C, Denick R (1994) Molecular basis of Fabry disease: Mutations and polymorphisms in the human alfa-galactosidase A gene. Hum Mut 3: 103-111.
8. Eng C, Guffon N, Wilcox WR, et al (2001) Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease. N Engl J Med 345: 9-16.
9. Eto Y, Ohashi T, Utsunomiya Y, et al (2005) Enzyme replacement therapy in Japanese Fabry disease patients: The results of a phase 2 bridging study. J Inherit Metab Dis 28 (4): 575-583.
10. Gomes I, Nora D, Becker J, et al (2003) Nerve conduction studies, electromyography and sympathetic skin response in Fabry's disease. J Neurol Sci 214: 21-25.
11. Hahoff D, Enever Y, Quiney R, Zuckerman J, Macdermot K, Mehta (2003) Hearing loss in Fabry disease: The effect of agalsidase alfa replacement therapy. J Inherit Metab Dis 26: 787-794.
12. Hilz MJ, Stemper B, Kolodny EH (2000) Lower limb cold exposure induces pain and prolonged small fibre dysfunction in Fabry patients. Pain 84: 361-365.
13. Hilz MJ, Brys M, Marthol H, Stemper B, Dütsch M (2004) Enzyme replacement therapy improves function of C, Aδ-, and A& beta;-nerve fibres in Fabry neuropathy. Neurology 62: 1066-1072.
14. Jardim LB, Vedolin L, Schwartz IVD, et al (2004) CNS involvement in Fabry's disease: Clinical and image studies before and after 12 months of enzyme replacement therapy. J Inherit Metab Dis 27(2): 229-240.
15. Kolodny EH, Pastores GM (2002) Anderson-Fabry disease: Extrarenal, neurologic manifestations. J Am Soc Nephrol 13: S150-S153.
16. Luciano CA, Russell JW, Banerjee T, et al (2002) Physiologic characterization of neuropathy in Fabry disease. Muscle Nerve 26: 622-629.
17. MacDermot KD, Holmes A, Miners AH (2001) Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 38: 750-760.
18. Mehta A, Ricci R, Widmer U, et al (2004) Fabry disease defined: Baseline clinical manifestations of 366 patients in the Fabry outcome survey. Eur J Clin Invest 34 (March): 236-242.
19. Schiffmann R, Scott LJ (2000) Pathophysiology and assessment of neuropathic pain in Fabry disease. Acta Paediatr Suppl 91: 48-52.
20. Schiffman R, Kopp JB, Austin HA, et al (2001) Enzyme replacement therapy in Fabry disease. A randomised controlled trial. JAMA 285: 2743-2749.
21. Schiffmann R, Floeter MK, Dambrosia JM, et al (2003) Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease. Muscle Nerve 28: 703-710.
22. Shahani BT, Halperin JJ, Boulu P, Cohen J (1984) Sympathetic skin response: A method of assessing unmyelinated axon dysfunction in peripheral neuropathies. J Neurol Neurosurg Psychiatry 47: 536-542.
23. Syed NA, Sandbrink, Luciano CA, et al (2000) Cutaneous silent periods in patients with Fabry disease. Muscle Nerve 23: 1179-1186.
24. Thurberg BL, Byers HR, Granter SR, Phelps RG, Gordon RE, O'Callaghan M (2004) Monitoring the 3 year efficacy of enzyme replacement therapy in Fabry disease by repeated skin biopsies. J Invest Dermatol 122: 900-908.
25. Weidemann F, Breunig F, Beer M, et al (2003) Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease. Circulation 108: 1299-1301.
26. Wilcox WR, Banikazemi M, Guffon N, et al (2004) Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 75: 65-74.
27. Yamamoto K, Sobue G, Iwase S, Kumazawa K, Mitsuma T, Mano T (1996) Possible mechanism of anhidrosis in a symptomatic female carrier of Fabry's disease: An assessment by skin sympathetic nerve activity and sympathetic skin response. Clin Auton Res 6(2):107-110.